JAMA:研究发现22种癌症属于遗传疾病

2016-01-18 全球肿瘤医生 全球肿瘤医生

哈佛大学科学家与丹麦和芬兰研究员合作进行的研究发现,至少有22种癌症属于遗传疾病,会在家族之间世代相传。根据这项大型研究的结果,大约三分之一的癌症是遗传的。家族遗传风险最高的包括前列腺癌、乳癌、肺癌和肠癌。科学家发现,如有同胞手足得这些癌症,其他兄弟姊妹得同样癌症的风险会提高33%。这是有史以来规模最大的历时最长的研究遗传与癌症之间关系的研究。研究发现不同的癌症, 遗传风险也不同。其中黑色素瘤和睾

哈佛大学科学家与丹麦和芬兰研究员合作进行的研究发现,至少有22种癌症属于遗传疾病,会在家族之间世代相传。

根据这项大型研究的结果,大约三分之一的癌症是遗传的。家族遗传风险最高的包括前列腺癌、乳癌、肺癌和肠癌。科学家发现,如有同胞手足得这些癌症,其他兄弟姊妹得同样癌症的风险会提高33%。这是有史以来规模最大的历时最长的研究遗传与癌症之间关系的研究。研究发现不同的癌症, 遗传风险也不同。其中黑色素瘤和睾丸癌与遗传的关系最为密切。

总体的研究结果并不令人惊讶,而是进一步证实了早先的研究结果,即约1/3的癌症病例是由于基因缺陷引起的,其余的大多数归咎于所谓的生活方式因素,如吸烟、饮食和运动。

不同类型的癌症,遗传风险不同

由哈佛公共卫生学院Lorelei Mucci领导的研究小组在美国医学协会杂志上报道,目前发现约38%的肾脏癌、31%的乳腺癌、27%的子宫癌、58%的黑色素瘤、57%的前列腺癌和39%的卵巢癌与遗传有关。

研究人员表示,超过8%的儿童癌症患者家族中存在意料之外的的基因突变。这些突变不仅使孩子们在未来存在癌症的风险,也可能意味着他们的父母、兄弟姐妹也有一个非常高的患癌风险。Jude儿童研究医院的孟菲斯认为,研究结果不仅用新的方法来检测孩子和他们的家属存在的癌症风险,也可能会找到更好的方法来治疗他们。

这项研究从1943到2010年,对瑞典、挪威、丹麦和芬兰的20多万对双胞胎进行追踪调查,对每个人平均追踪32年。这种大规模双胞胎研究,使科学家得以评估遗传因素对癌症的重要性,并借着衡量同卵和异卵双胞胎的基因异同,评估家族罹癌风险。同卵双胞胎的基因是完全相同的,而异卵双胞胎的基因只是相似,所以这两者中患癌风险的差异明确指向为遗传因素。

Mucci的研究小组还发现,有38%的同卵双胞胎和26%的异卵双胞胎被诊断为癌症。当双胞胎中的其中一人确诊患癌后,另一人患癌的风险会显着增加,异卵双胞胎的风险为37%,而同卵双胞胎的风险则高达46%。南丹麦大学的Jacob Hjelmborg说:“由于本次研究规模庞大,跟踪时间长,我们可以看到关键基因对多种类型癌症的影响。”

睾丸癌的遗传风险很高。如果一个人的异卵双胞胎兄弟患有睾丸癌,那么他患睾丸癌的风险会增加12倍。而对同卵双胞胎来说,一人患睾丸癌,另一人患睾丸癌的风险则会增加28倍。

调查小组还发现:大约1%的人得到了黑色素瘤,这是皮肤癌的最致命的形式。如果异卵双胞胎中一人患有黑色素瘤,另一人患黑色素瘤的风险为6%,而对同卵双胞胎来说,另一人患黑色素瘤的风险为20%。

患前列腺癌和乳腺癌的风险可能是由于他们小时候共处在一个子宫内,两者都强烈地受到激素的影响,包括那些影响胎儿生长的激素。肺癌受环境影响较大,可能是由于双胞胎的吸烟习惯大多相同。

需要注意的是,在参加了该项研究的北欧国家中,癌症是引起死亡的第一大原因。在美国及其他发达国家中,癌症是引起死亡的第二大原因,仅次于心脏病。

原始出处:

Familial Risk and Heritability of Cancer Among Twins in Nordic Countries.JAMA.2016;315(1):68-76. doi:10.1001/jama.2015.17703.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-03-18 1ddc978cm67(暂无匿称)

    谢谢分享。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-03-18 1ddc978cm67(暂无匿称)

    谢谢分享。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-03-18 1ddc978cm67(暂无匿称)

    谢谢分享。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-01-21 小小凡

    。。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-01-18 忠诚向上

    长知识

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1667068, encodeId=bb71166e068cc, content=<a href='/topic/show?id=93d7951895b' target=_blank style='color:#2F92EE;'>#遗传疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95189, encryptionId=93d7951895b, topicName=遗传疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8bd226091152, createdName=lvliquan, createdTime=Fri Jul 22 09:38:00 CST 2016, time=2016-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71548, encodeId=2c17e154824, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71549, encodeId=9a44e15496b, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=71550, encodeId=e6e1e15509f, content=谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Fri Mar 18 18:47:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753125, encodeId=00d81e531257a, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Fri Dec 09 20:38:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59944, encodeId=c5a6599449b, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59945, encodeId=24795994515, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 17:15:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58648, encodeId=65c858648d2, content=。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160513/IMG57353018A3FC59367.jpg, createdBy=1fba1648667, createdName=小小凡, createdTime=Thu Jan 21 12:56:00 CST 2016, time=2016-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58269, encodeId=f79458269a5, content=长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Jan 18 22:16:00 CST 2016, time=2016-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58257, encodeId=54215825ed9, content=人家的研究真是耐得住时间的考验!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Mon Jan 18 19:41:00 CST 2016, time=2016-01-18, status=1, ipAttribution=)]
    2016-01-18 Jianghuiqin

    人家的研究真是耐得住时间的考验!

    0

相关资讯

Cancer Cell:科学家或可成功预测白血病的发生

最近,发表于国际杂志Cancer Cell上的一项研究论文中,来自麦克马斯特大学等处的研究人员通过研究成功鉴别出了致死性癌症的早期发病阶段,同时也成功预测了这种疾病在机体中的发病机制。 研究人员Mick Bhatia教授指出,我们发现了从健康到癌性的血液干细胞的过渡常常发生在有区别的过程中,这项研究中我们鉴别出了两个关键的步骤。文章中研究人员对骨髓增生异常综合征(MDS)成功地进行了指纹图谱分析

JAC:食品天然防腐剂显神效 或可杀灭癌细胞

乳酸链球菌素是一种在乳制品中存在的天然食物防腐剂,其或许可以对两种人类疾病进行终极消灭,即对癌症和致死性耐药性细菌进行杀灭作用。近日一项刊登在国际杂志the Journal of Antimicrobial Chemotherapy上的研究论文中,来自密歇根大学的研究人员通过研究发现,服用含乳酸链球菌素奶昔的大鼠在9周后机体中有70%至80%的头颈癌肿瘤细胞会死亡,而且大鼠的生存期会延长。 随后

Cell Metab:惰性炎症是肥胖诱导癌症发生的关键机制

南京医科大学孙倍成教授和加州大学的研究人员在本期Cell Metabolism杂志上发表文章,全面探讨了肥胖与癌症之间的复杂关系。文章的通讯作者是南京医科大学第一临床医学院的孙倍成教授和加州大学圣地亚哥分校的Michael Karin。


营养过度会导致脂肪过量堆积和异常分布,引起令人头疼的慢性代谢疾病——肥胖。肥胖症在现代社会的流行已经成为了老生常谈的话题,但这种疾病对公共健康的影响仍是不可忽视的。
肥胖会造成胰岛素、血糖和血脂水平紊乱,进而引发高血压、Ⅱ型糖尿病、非酒精性脂肪肝、动脉粥样硬化等代谢问题。除此之外,肥胖还会让人更容易患上某些癌症。

奥巴马提出癌症“登月计划”,继精准医疗后新医学蓝图

美国总统巴拉克·奥巴马并不打算悄悄离去。他在1月12日对国会发表的国情咨文中宣布将发起一项寻找癌症治愈疗法的“登月计划”,由此开启了自己在白宫的最后一年任期。 奥巴马在演讲中说,美国副总统乔·拜登去年曾说过,如果发起一个新的“登月计划”,美国将能治愈癌症。 上个月,拜登与国会合作给美国国立卫生研究院提供了过去10多年来最有力的预算支持。奥巴马宣布发起“新的国家努力”,拜登将担任该计划的

奥巴马提出癌症“登月计划”

美国总统巴拉克·奥巴马并不打算悄悄离去。他在1月12日对国会发表的国情咨文中宣布将发起一项寻找癌症治愈疗法的“登月计划”,由此开启了自己在白宫的最后一年任期。 美国总统奥巴马将于2017年1月结束任期。图片来源:Jim Bourg 奥巴马在演讲中说,美国副总统乔·拜登去年曾说过,如果发起一个新的“登月计划”,美国将能治愈癌症。 上个月,拜登与国会合作给美国国立卫生研究院提供了

Ann Intern Med:儿童期癌症患者使用心脏毒性药物后,成年期心脏疾病情况

研究者对1853名≥18岁的儿童期癌症患者进行了一项横断面研究,探究使用了癌症相关具有心脏毒性治疗的患者,10年或更长时间以后的心脏结局。研究者获取了参与者基础病史、体格检查、代谢、超声心动图、心电图、6分钟步行距离试验等数据。在诊断癌症时候有52.3%的是男性,中位数年龄8岁(0-24岁),在中位数31岁(18-60岁)对其进行评估。研究数据显示,7.4%的幸存者出现过心肌病(评估期间新诊断的占